Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Clinical Trials

 
A.    Approval of Clinical Trials in Lebanon

This section has been developed for individuals and organizations involved in health-related research with human participants. In particular, this document is intended to provide guidance to design and carry out health research studies to provide guidance on the requirements of the Lebanese Ministry of Public Health to approve a clinical trial in Lebanon.
 

B.    Authorization of Institutional Review Boards (IRBs)/Research Ethics Commitees (RECs)

This section has been developed to give guidance to hospitals and universities who have their own IRBs/RECs on the requirements needed by the Lebanese Ministry of Public Health to be officially authorized to be allowed to review and oversee the ethical aspects of research that involve human subjects. Hospitals and centers who do not have their own IRBs/RECs are allowed to be affiliated with authorized IRBs/RECs per the requirements of the Ministry.
 
List of Authorized IRBs
تؤكد وزارة الصحة العامة على جميع المستشفيات و المراكز التي ترغب باجراء دراسات سريرية و ابحاث تستهدف الانسان بضرورة الالتزام بالقرار رقم 141/1 تاريخ 27 كانون الثاني 2016  لجهة التقدم بطلب لوزارة الصحة العامة للاعتراف رسمياً بلجنة اخلاقيات الابحاث  Institutional Review Board (IRB)التابعة لها او التعاقد مع مستشفى او مركز  لديه  IRB معترف بها رسمياً من الوزارة.
و تود وزارة الصحة العامة التذكير بان المهلة المعطاة لتقديم المستندات المطلوبة تنتهي في 27 كانون الثاني 2017, و بناءاً عليه لن توافق الوزارة على اي دراسة سريرية خارج هذا الاطار بعد هذا التاريخ.
 
تجدون ربطاً لائحة الجامعات والمستشفيات التي قدمت طلبات للإعتراف بلجان الأخلاقيات  للتجارب السريرية التابعة لها والطلبات التي تمت دراستها و الطلبات التي تمت الموافقة عليها.
 
 
 
C.     Exportation of Biological Samples as part of clinical trials

This section is developed to give guidance to researchers and sponsors who wish to export biological samples (blood, urine, etc) to be tested outside the country as part of clinical trials protocols on the requirements needed to obtain the approval from the ministry.
 

D.     Lebanon Clinical Trials Registry (LBCTR)

The Lebanese Clinical Trials Registry (LBCTR) is an online register of clinical trials being undertaken in Lebanon. The LBCTR will include trials that target humans; from the full spectrum of therapeutic areas of pharmaceuticals, surgical procedures, preventive measures, lifestyle, devices, treatment and rehabilitation strategies and complementary therapies.

The LBCTR will allow registration for interventional as well as observational studies.
  • The MOPH is the owner and the sole manager of the LBCTR.
  • All details of trials registered on the LBCTR will be made publicly available.
  • The registration of Interventional studies will be mandatory and observational studies will be voluntary.
  • The registration of studies is free of charge.
  • The responsibility for registration lies with the sponsor.
  • The sponsor is defined as:  an individual, company or institution or organization which takes responsibility for the initiation, management and/or financing of a clinical trial.
  • It is the sponsor's responsibility to ensure that the information submitted is accurate and up-to-date.
LBCTR PUBLIC & APPLICANT USER GUIDE
 
Go to LBCTR website
 
    ...
    6
ATC Name B/G Ingredients Dosage Form Price
N05AX08 RISPERDAL B Risperidone - 2mg 2mg Tablet 306,396 L.L
N05AX08 RESPAL 2 G Risperidone - 2mg 2mg Caplet, film coated 342,680 L.L
N05AX08 RISPERIDONE BIOGARAN G Risperidone - 2mg 2mg Tablet, coated, scored 1,488,977 L.L
N03AE01 RIVOTRIL B Clonazepam - 2mg 2mg Tablet, scored 503,941 L.L
N05AX08 RISCHOTIC OD 2 G Risperidone - 2mg 2mg Tablet, orally disintegrating 371,157 L.L
N05AX16 REXULTI B Brexpiprazole - 2mg 2mg Tablet, film coated 13,433,051 L.L
A06AX05 RESOLOR B Prucalopride succinate - 2mg 2mg Tablet, film coated 5,251,736 L.L
J06BB01 RHOPHYLAC 300 BioHuman Human anti-D (rh) immunoglobulin - 300mcg/2ml 300mcg/2ml Injectable solution 5,939,784 L.L
N05AH04 REZAL XR G Quetiapine fumarate - 300mg 300mg Tablet, extended release 2,535,831 L.L
J05AF01 REVODINE G Zidovudine - 300mg 300mg Tablet, film coated 7,771,552 L.L
C01BC03 RYTMONORM B Propafenone HCl - 300mg 300mg Tablet, film coated 1,715,447 L.L
N06AX11 REMERON SOLTAB B Mirtazapine - 30mg 30mg Tablet, orodispersible 1,486,290 L.L
M05BA07 RISEDRONATE ARROW G Risedronate sodium - 35mg 35mg Tablet, film coated 671,921 L.L
C01EB18 RANEXA B Ranolazine - 375mg 375mg Tablet, prolonged release 3,985,837 L.L
N06DA03 RIVASTIGMINE ARROW G Rivastigmine - 3mg 3mg Capsule 842,589 L.L
N05AX08 RISCHOTIC OD 3 G Risperidone - 3mg 3mg Tablet, orally disintegrating 605,369 L.L
N05AX15 REAGILA G Cariprazine HCl - 3mg 3mg Capsule, hard 6,394,003 L.L
N05AX16 REXULTI B Brexpiprazole - 3mg 3mg Tablet, film coated 13,433,051 L.L
N06DA03 RIVASTIGMINE ARROW G Rivastigmine - 3mg 3mg Capsule 842,589 L.L
J01FA02 ROVAMYCINE B Spiramycin - 3MIU 3MIU Tablet, film coated 649,076 L.L
N06DA03 RIVASTIGMINE ARROW G Rivastigmine - 4.5mg 4.5mg Capsule 842,589 L.L
N06DA03 RIVASTIGMINE ARROW G Rivastigmine - 4.5mg 4.5mg Capsule 842,589 L.L
N05AX15 REAGILA G Cariprazine HCl - 4.5mg 4.5mg Capsule, hard 6,394,003 L.L
C10AA07 ROSUCOR G Rosuvastatin (calcium) - 40mg 40mg Tablet, film coated 487,623 L.L
C10AA07 ROXARDIO G Rosuvastatin (calcium) - 40mg 40mg Tablet, film coated 682,094 L.L
C10AA07 ROSUPHAR G Rosuvastatin (calcium) - 40mg 40mg Tablet, film coated 487,623 L.L
A02BC01 RISEK G Omeprazole - 40mg 40mg Capsule, enteric coated 522,755 L.L
A02BC01 RISEK G Omeprazole (sodium) - 40mg 40mg Injectable lyophilised powder for solution 592,635 L.L
A02BC02 RAZON 40 G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 727,019 L.L
A02BC02 RAZON 40 G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 1,252,461 L.L
    ...
    6
Sitemap
© Copyrights reserved to Ministry of Public Health 2025